Prevalence and characteristics of HPV-driven oropharyngeal cancer in France

Haitham Mirghani (1, 2) , Carine Bellera (3) , Jessy Delaye (4) , Gilles Dolivet (5) , Nicolas Fakhry (6) , Alexandre Bozec (7) , Renaud Garrel (8) , Olivier Malard (9, 10) , Franck Jegoux (11) , Philippe Maingon (12) , Jérôme Sarini (13) , Georges Noel (14) , Suzy Duflo (15) , Stéphane Temam (16) , Jean-Louis Lefebvre (17) , Valérie Costes-Martineau (18, 19)

1 LPP - LPP - Laboratoire de Phonétique et Phonologie - UMR 7018
2 IGR - Institut Gustave Roussy
3 Centre d'Investigation Clinique - Epidemiologie Clinique / Essais Cliniques Bordeaux
4 Institut Curie [Paris]
5 UNICANCER/ICL - Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy]
6 ORL et Chirurgie cervico-faciale pédiatrique - [Hôpitaux Timone et Nord - APHM]
7 UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice]
8 CHRU de Montpellier - Service ORL [Hôpital Gui de Chauliac]
9 LIOAD - Laboratoire d'ingénierie osteo-articulaire et dentaire
10 CHU Nantes - Centre Hospitalier Universitaire de Nantes
11 Centre Hospitalier Universitaire [Rennes]
12 UNICANCER/CRLCC-CGFL - Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon]
13 Institut Claudius Regaud
14 CRLCC Paul Strauss - Centre Paul Strauss
15 CHU Pointe-à-Pitre/Abymes [Guadeloupe]
16 CCF - Département de cancérologie cervico-faciale [Gustave Roussy]
17 UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille]
18 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
19 Pathogénèse et contrôle des infections chroniques (PCCI)

Background: France has one of the highest incidence of head and neck cancers in Europe. Despite this, the epidemiological impact of high-risk human papilloma virus (HR-HPV) remains poorly investigated. Methods: we prospective assessed the proportion of oropharyngeal cancers due to HR-HPV in 15 hospitals throughout France. HPV-status was determined by p16-immunohistochemistry, and by detection of HPV-DNA using in situ hybridization. Cancers were classified as HPV-driven if both p16-immunohistochemistry and HPV-DNA assays were positive. Demographical and clinical features were recorded. Results: 291 patients with palatine-tonsil or tongue-base cancers were recruited from March-2011 to July-2012. Of these, 43.1% of samples were p16-positive and 37.7% were positive for both p16 and HPV-DNA. Prognosis was significantly better in patients with HPV-driven cancers, with smoking negatively impacting patients' oncological outcomes. Conclusion: in France, more than a third of tonsillar and tongue base cancers are HPV-driven. More research concerning the evolution of HPV-driven cancers over time is needed.

Mots clés: France; Human papillomavirus (HPV); Cancer(s); Epidemiology; Neoplasm(s); Oral/oropharynx/oropharyngeal; Prevalence; Tonsil/tonsillar

Domaines: Cancer

Haitham Mirghani, Carine Bellera, Jessy Delaye, Gilles Dolivet, Nicolas Fakhry, et al.. Prevalence and characteristics of HPV-driven oropharyngeal cancer in France. Cancer Epidemiology, 2019, 61, pp.89-94. ⟨10.1016/j.canep.2019.05.007⟩. ⟨hal-02771653⟩